Menlo Park, CA – 5AM Venture Management, LLC (5AM) of Menlo Park, CA and Waltham, MA is pleased to announce the closing of 5AM Ventures IV, L.P., a $250 million venture capital fund focused on the building of life science companies. The capital was raised from a broad range of existing and new institutional investors including endowments, family offices, foundations, funds-of-funds and pension funds.

Created by successful industry executives and experienced venture capitalists, the 5AM team takes a focused, hands-on approach to company building. 5AM portfolios are well diversified, including innovative platform technologies, spinouts from established life science companies, and companies developing near-term products. 5AM will continue to target early-stage life science companies with most of its investments focused on the discovery and development of novel therapeutics.

5AM's investment team consists of Managing Partners John Diekman, Ph.D., Scott Rocklage, Ph.D., and Andy Schwab; Venture Partners Mason Freeman, M.D., Richard Ulevitch, Ph.D. and Jim Young, Ph.D.; Principals Mark Colella, Kevin Forrest, Ph.D. and Kush Parmar, M.D., Ph.D., General Counsel & COO Paul Stone, J.D. and Vice President, Finance, Jenny Lee.

About 5AM Ventures

Founded in 2002, 5AM Ventures actively invests in next-generation life science companies. With over $685 million under management, 5AM has invested in 40 early-stage companies and successful exits include Alexza Pharmaceuticals (Nasdaq: ALXA), Envoy Therapeutics (sold to Takeda), Ilypsa (sold to Amgen), Incline Therapeutics (sold to The Medicines Company), KaloBios (Nasdaq: KBIO), Marcadia (sold to Roche), Miikana Therapeutics (sold to EntreMed), Panomics (sold to Affymetrix), Pearl Therapeutics (sold to AstraZeneca), Relypsa (Nasdaq: RLYP), Semprus (sold to Teleflex) and Synosia Therapeutics (sold to Biotie Therapies). For more information, please visit www.5amventures.com.

Suggested Articles

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.

The readout is a key moment in the history of the drug and Mirati, shares in which have soared in the updraft created by data on Amgen’s rival asset.